Mohamedtaki Tejani, MD, FACS

Mohamedtaki Tejani, MD, FACS

Medical Director - Gastrointestinal (GI) Oncology Program

Cancer

Tejani

Overview

Mohamedtaki A. Tejani, MD, received his Bachelor of Arts degree, Magna Cum Laude, from Amherst College. He later earned his medical degree from Dartmouth Medical School. Dr. Tejani went on to complete his residency at Yale-New Haven Hospital in New Haven, CT, achieving the rank of Chief Resident. Following this, he completed his fellowship training in hematology/oncology at Fox Chase Cancer Center/Temple University in Philadelphia. An award-winning physician, Dr. Tejani has authored numerous oncology-related publications. His research experience and areas of interest include gastrointestinal cancers, biomarkers and therapeutics, patient-provider communication and the culture of medicine. Dr. Tejani firmly believes that patient care is a privilege. Listening and responding to a patient’s unique story is critical in helping that family on their cancer journey. Originally from Tanzania (East Africa), he is fluent in Swahili, Hindi, Urdu and Gujarati.

Articles

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma

The oncologist

2022

A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)

ANNALS OF ONCOLOGY

2022

Associations of Uncertainty With Psychological Health and Quality of Life in Older Adults With Advanced Cancer

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

2021

Comparing Needles and Methods of Endoscopic Ultrasound-Guided Fine-Needle Biopsy to Optimize Specimen Quality and Diagnostic Accuracy for Patients With Pancreatic Masses in a Randomized Trial

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

2021

A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.

JOURNAL OF CLINICAL ONCOLOGY

2021

DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

ANNALS OF ONCOLOGY

2021

Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience

CLINICAL COLORECTAL CANCER

2020

Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma

ANNALS OF THORACIC SURGERY

2019

Opportunities for cannabis in supportive care in cancer

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

2019

Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design

FUTURE ONCOLOGY

2019

More Publication Information

Education & Training

Education

University of Rochester School of Medicine, Rochester, NY

Residency

Yale-New Haven Medical Center, New Haven, CT

Fellowship

Fox Chase Cancer Center/Temple University, Philadelphia, PA

Associated Clinical Trials

NCT04793958

A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Icon for trial | 849-010 A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

This study is currently enrolling.

This is a study involving an investigational (experimental) drug called MRTX849, being developed by Mirati Therapeutics, Inc., which is the company that provides MRTX849 study drug and is funding and organizing the study. Inves ...

NCT04935359

A randomized, three-arm, double-blind, placebo-controlled, phase III study, comparing NIS793 with or without spartalizumab in combination with gemcitabine and nab-paclitaxel versus matching placebos combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

Icon for trial | CNIS793B12301 A randomized, three-arm, double-blind, placebo-controlled, phase III study, comparing NIS793 with or without spartalizumab in combination with gemcitabine and nab-paclitaxel versus matching placebos combined with gemcitabine and nab-paclitax

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC. This study aims to explore whether blo ...

NCT05111626

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Cancer With FGFR2b Overexpression

Icon for trial | 20210098 A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Cancer With FGFR2b Overexpression

This study is currently enrolling.

You are being asked to take part in Part 2 of this study because you have advanced gastric cancer (a disease in which cancer cells form in the lining of the stomach) or gastroesophageal junction cancer (a type of cancer forming ...

NCT05330429

GS-US-587-6156: A phase 2 study to evaluate the efficacy and safety of magrolimab in combination with bevacizumab and FOLFIRI in previously treated, advanced inoperable metastatic colorectal cancer (CRC) patients

Icon for trial | AHORL_1897619 GS-US-587-6156: A phase 2 study to evaluate the efficacy and safety of magrolimab in combination with bevacizumab and FOLFIRI in previously treated, advanced inoperable metastatic colorectal cancer (CRC) patients

This study is currently enrolling.

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal ...

NCT05610163

THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

Icon for trial | A022104 THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

This study is currently enrolling.

To evaluate and compare the cCR rates in patients with locally advanced rectal cancer treated with neoadjuvant LCRT followed by neoadjuvant mFOLFIRINOX versus neoadjuvant LCRT followed by neoadjuvant mFOLFOX6.To evaluate and co ...

NCT04952753

An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer

Icon for trial | CNIS793E12201 An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic col

We are inviting you to be in a research study to find out if adding an investigational compound NIS793 by itself or in combination with a compound tislelizumab to standard anti-cancer therapy can potentially improve treatment o ...